drugset / Trial / NCT02076659
Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients
NaSingle-groupOpen-labelTreatment
Summary
Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.
Timeline
- Start
- 2011-09
- Primary completion
- 2017-04
- Completion
- 2017-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F8IL10 | Monoclonal antibody | 6 ug/kg | Subcutaneous |
| Subject | F8IL10 | Monoclonal antibody | 600 ug/kg | Subcutaneous |
| Background | Methotrexate | Small molecule | 10 mg | Oral |
| Background | Methotrexate | Small molecule | 15 mg | Oral |